Sökning: id:"swepub:oai:DiVA.org:oru-70214" >
A Swedish nationwid...
-
Fält, A.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
(författare)
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2)
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
Sage Publications,2018
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:oru-70214
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-70214URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:vet swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies:Novartis Biogenldec Merck-Serono TEVA Sanofi-Genzyme Bayer-Schering Merck Serono Sanofi Genzyme
-
Background: Fingolimod (FGL) is an oral therapy for patients with relapsing-remitting multiple sclerosis (RRMS) and the efficacy has been shown in phase II and III studies. However; long-term surveillance and safety is important, therefore FGL is included in the Swedish “Immunomodulation and Multiple Sclerosis Epidemiology Study 2” (IMSE 2).Objective: To follow up the effectiveness and long-term safety of FGL in a real-world setting.Methods: Swedish MS patients are registered into the nationwide Swedish Neuro Registry (NeuroReg). IMSE 2 includes data of adverse events (AEs) and clinical measures; Extended Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), Symbol Digit Modalities Test (SDMT), Multiple Sclerosis Impact Scale (MSIS-29), European Quality of Life - 5 Dimension Test (EQ-5D) and Visual Analogue Scale (VAS), obtained from NeuroReg.Results: From September 2011 until April 2018, 1617 patients (67% female; 91% RRMS) were included in IMSE 2. At treatment start 38 patients were ≤20 years (yr), 308 aged 21-30 yr and 1271 aged >30 yr. Mean treatment duration was 34 months. 852 patients were currently treated with FGL at cut-off date and 1230 patients had been treated for at least 12 months. In total, 39% switched treatment from interferons or glatiramer acetate, 26% from natalizumab and 5% from dimethyl fumarate or teriflunomide. 803 patients have discontinued FGL at some point, mainly due to lack of effect (43%) or AEs (34%), most patients switched to rituximab after FGL discontinuation. Relapses were reduced from 281 to 87/1000 patient years (PY) when comparing before and during FGL treatment. In patients aged ≤20 yr, 21-30 yr and >30 yr relapses were reduced from 694 to 144/1000 PY, 455 to 129/1000 PY and 258 to 77/1000 PY, respectively. After 12 months significant improvements were seen in EQ-5D (0.7 to 0.8, n=752), MSSS (3.1 to 2.9, n=410), MSIS-29 Physical (21.1 to 20.0 n=812), MSIS-29 Psychological (29.2 to 24.9, n=812), SDMT (54.3 to 57.0, n=751) and VAS (70.9 to 72.8, n=692). When analysing age groups separately significant improvements were seen in MSSS, SDMT, and MSIS-29 Psychological in patients aged 21-30 yr and >30 yr. EQ-5D, VAS and MSIS-29 Physical significantly improved in patients aged >30 yr.Conclusions: FGL is a generally well-tolerated drug that reduces the clinical activity in MS patients. NeuroReg functions well as a drug surveillance platform, enabling monitoring of long-term effectiveness and AEs.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Kågström, S.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
(författare)
-
Demirbüker, S. SaferDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
(författare)
-
Hillert, J.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
(författare)
-
Nilsson, P.Department of Neurology, Lund University, Lund, Sweden
(författare)
-
Dahle, C.Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
(författare)
-
Svenningsson, A.Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
(författare)
-
Lycke, J.Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, Gothenburg, Sweden
(författare)
-
Landtblom, A. -MDepartment of Neuroscience, Uppsala University, Uppsala, Sweden
(författare)
-
Burman, J.Department of Neuroscience, Uppsala University, Uppsala, Sweden
(författare)
-
Martin, C.Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
(författare)
-
Sundström, P.Department of Clinical Neuroscience, Umeå University, Umeå, Sweden
(författare)
-
Gunnarsson, Martin,1973-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Neurology(Swepub:oru)mign
(författare)
-
Piehl, F.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
(författare)
-
Olsson, T.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
(författare)
-
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SwedenDepartment of Neurology, Lund University, Lund, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Multiple Sclerosis Journal: Sage Publications24:Suppl. 2, s. 696-6971352-45851477-0970
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Fält, A.
-
Kågström, S.
-
Demirbüker, S. S ...
-
Hillert, J.
-
Nilsson, P.
-
Dahle, C.
-
visa fler...
-
Svenningsson, A.
-
Lycke, J.
-
Landtblom, A. -M
-
Burman, J.
-
Martin, C.
-
Sundström, P.
-
Gunnarsson, Mart ...
-
Piehl, F.
-
Olsson, T.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Multiple Scleros ...
- Av lärosätet
-
Örebro universitet